A randomized, double-blinded study evaluating effect of matcha green tea on human fecal microbiota

Data1_Fecal_Evaluation_The defecation frequency and Bristol Stool Form Scale for Table 1. Data2_Alpha_Diversity_Alpha Diversity for gut microbiota used for Table 2. Data3_Microbiota_MGT_Abundance for bacterial genus of MGT group used for Table 4. Data4_Microbiota_Placebo_Abundance for bacterial genus of Placebo group used for Table 3.</p

Baseline characteristics of patients.

<p>ARB, angiotensin II receptor blocker; IQR, interquartile range.</p><p>Baseline characteristics of patients.</p

Changes in the levels of hemoglobin and albumin after treatment with placebo or rebamipide.

<p>Results are expressed as medians and interquartile ranges (IQRs)</p><p>Changes in the levels of hemoglobin and albumin after treatment with placebo or rebamipide.</p

Changes in the number of small intestinal mucosal breaks from baseline to posttreatment.

<p>Results were analyzed by the Wilcoxon signed-rank test.</p

Changes in the severity of small intestinal mucosal breaks from baseline to posttreatment.

<p>Results were analyzed by McNemar test.</p

Capsule endoscopic images of small bowel mucosal breaks induced by low-dose enteric-coated aspirin.

<p>Typical photographs of mucosal breaks observed in this study are shown. A: a mucosal break (arrow). B: multiple mucosal breaks (arrows).</p

Trial flow diagram.

<p>Trial flow diagram.</p

Additional file 1: of Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Table S1. Summary of NK cell expansion from 31 cancer patients (supplementary information of reference #25)

SLC38A9 SNPs of IBD patients.

<p>SLC38A9 SNPs were determined by correlation analysis with genotypes and 6-TGN risk ratios in IBD patients.</p

Results of drug-induced EAI for SNP (rs6897117) of SLC38A9.

<p>The SNP of SLC38A9 shows a consistent relationship between 6-TGN risk ratios and drug-induced EAI.</p